Alexion Pharmaceuticals, Inc.
METHODS FOR TREATMENT OF REFRACTORY GENERALIZED MYASTHENIA GRAVIS
Last updated:
Abstract:
The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody.
Status:
Application
Type:
Utility
Filling date:
15 Jan 2021
Issue date:
12 Aug 2021